Prediction of response to pegylated-interferon-α and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype

BACKGROUND: The standard treatment for patients with chronic hepatitis C (CHC), pegylated interferon-α (PEG-IFN) plus ribavirin (RBV) does not provide a sustained virological response (SVR) in all patients. Genetic variations at the interleukin 28B (IL-28B) locus are important in predicting outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Guo, Xiaoyan, Zhao, Zhixin, Xie, Junqiang, Cai, Qingxian, Zhang, Xiaohong, Peng, Liang, Gao, Zhiliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439299/
https://www.ncbi.nlm.nih.gov/pubmed/22713131
http://dx.doi.org/10.1186/1743-422X-9-123

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3439299/
https://www.ncbi.nlm.nih.gov/pubmed/22713131
http://dx.doi.org/10.1186/1743-422X-9-123

Ejemplares similares